Kenvue
Kenvue owns Tylenol, Band-Aid, Neutrogena, and Listerine as a standalone consumer health company.
On the record
Checkpoint: Kimberly-Clark merger closing, pending remaining foreign regulatory approvals
The call
Kenvue's brands have real regulatory and shelf protection, but the company itself is mid-merger into Kimberly-Clark and will stop existing as an independent stock within months.
Kenvue sells over-the-counter medicines and personal care products like Tylenol, Band-Aid, and Neutrogena. These brands have strong shelf space and regulatory approval that make them hard for competitors to replace overnight, but Kenvue's sales have been falling and the company is being absorbed into Kimberly-Clark by the middle of 2026, so it will stop being independent very soon. The biggest wild card is a legal fight over whether Tylenol caused autism or ADHD in children: if courts allow this lawsuit to move forward and damages pile up, it could hurt the combined company's earnings and change how investors view the deal.
Why
01
AI pressure: Amazon's Rufus and retailer AI shopping assistants pushing store-brand alternatives. AI shopping assistants can steer buyers toward cheaper store-brand pain relief and skincare instead of Tylenol or Neutrogena at checkout. Could AI do the core job? Unlikely.
02
Bigger players: Kimberly-Clark Corporation. Kimberly-Clark signed a $48.7B deal to buy Kenvue outright, shareholders approved it Jan 29, 2026, close targeted for H2 2026. Could a giant copy it? No, they are blocked.
03
What protects it. FDA-regulated OTC drug status, decades of brand trust, and locked-in shelf space make Tylenol and Band-Aid hard to displace fast.
What would change this call
Foreign antitrust regulators approve or block the Kimberly-Clark acquisition before H2 2026 close date. Confirms or disrupts the planned absorption of Kenvue into Kimberly-Clark.
District court Daubert ruling on Tylenol autism/ADHD causation experts after July 2026 remand. Determines whether litigation risk escalates into material damages for the combined entity.
Kenvue or combined KMB entity reports organic sales growth trend in Q2/Q3 2026 earnings. Shows whether the -2.2% decline is stabilizing or worsening ahead of merger close.
District court Daubert ruling on Tylenol autism/ADHD causation experts after July 2026 remand. Determines whether litigation risk escalates into material damages for the combined entity.
Kenvue or combined KMB entity reports organic sales growth trend in Q2/Q3 2026 earnings. Shows whether the -2.2% decline is stabilizing or worsening ahead of merger close.
Key numbers
- Kimberly-Clark deal valued at $48.7B enterprise value
- FY2025 organic sales fell 2.2%
- 2nd Circuit revived 500+ Tylenol autism lawsuits
Named risks
- Merger with Kimberly-Clark could face foreign regulatory delay or blockage before H2 2026 close.
- Tylenol autism/ADHD litigation revived by 2nd Circuit July 13, 2026 covering 500+ cases.
- Texas AG deceptive-marketing lawsuit over Tylenol/autism claims filed October 2025.
- Negative organic sales growth (-2.2% FY2025) reflects underlying demand weakness pre-merger.
- Post-merger integration cuts concentrated in HQ and corporate roles, job security risk for staff.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Kimberly-Clark | losing to | Signed definitive merger to absorb Kenvue Nov 3, 2025, close targeted H2 2026 |
| L'Oreal (CeraVe) | losing to | CeraVe documented taking share from Neutrogena in dermocosmetics per 2025-2026 brief |
| Haleon | contesting | Rival OTC consumer health company (Advil, Sensodyne) competing across same retail channels |
| Reckitt Benckiser | contesting | Competes in OTC/personal care (Mucinex, Durex, Dettol) against Kenvue brands |
| Procter & Gamble | contesting | Competes across personal care and OTC categories (Vicks, Crest) with Kenvue |
Questions people ask
- Is Kenvue still an independent company in 2026?
- Not for much longer. Kimberly-Clark signed a definitive merger agreement to acquire Kenvue on November 3, 2025 for roughly $48.7B enterprise value; shareholders approved it January 29, 2026, and close is targeted for H2 2026, ending Kenvue as a standalone public company.
- Is Kenvue profitable?
- Yes. Kenvue reported FY2025 net income of $1.47B on $15.1B revenue, though net sales fell 2.1% and organic sales fell 2.2% for the year (as of Feb 17, 2026). Q1 2026 showed improvement: net sales of $3.91B, up 4.5% YoY, with adjusted EPS of $0.32.
- Is Kenvue laying off employees?
- Yes. On February 17, 2026, Kenvue's board approved a global workforce reduction of about 3.5%, roughly 770 to 880 roles, ahead of the Kimberly-Clark merger, with about $250M in 2026 restructuring charges targeting $350M in annual savings.
- Could AI replace Kenvue's business?
- Unlikely in the core business. Kenvue makes FDA-regulated OTC drugs like Tylenol and physical goods like Band-Aid through regulated manufacturing and retail distribution. AI mainly touches marketing, forecasting, and analytics at the edges, not the regulated product or shelf-space moat, per the July 2026 evidence brief.
- Who is Kenvue's biggest competitor?
- Kenvue's biggest structural change isn't a competitor but its acquirer, Kimberly-Clark, which signed a deal November 3, 2025 to absorb it. In dermocosmetics, L'Oreal's CeraVe is documented taking share from Neutrogena; other rivals include Haleon, Reckitt, and P&G.
- What happened with the Tylenol autism lawsuits against Kenvue?
- On July 13, 2026, the 2nd U.S. Circuit Court of Appeals revived over 500 private lawsuits alleging acetaminophen-autism/ADHD links, vacating a December 2024 dismissal and remanding to district court. KVUE shares fell about 1.8% and KMB fell about 2.7% that day.
Timeline
- 2026-07-132nd Circuit revives 500+ Tylenol autism/ADHD lawsuits, remands to district court, KVUE and KMB shares drop
- 2026-05-07Kenvue reports Q1 2026 net sales of $3.91B, up 4.5% YoY, organic sales +0.7%
- 2026-02-17Kenvue reports FY2025 results, approves ~3.5% workforce cut and $250M restructuring charge
- 2026-02-04HSR antitrust waiting period expires for Kimberly-Clark/Kenvue merger
- 2026-01-29Shareholders of Kenvue and Kimberly-Clark approve merger deal
- 2025-11-03Kimberly-Clark and Kenvue sign definitive merger agreement, ~$48.7B enterprise value
- 2025-10-01Texas Attorney General files deceptive-marketing suit against J&J and Kenvue over Tylenol/autism claims
- 2025-07-14CEO Thibaut Mongon ousted amid activist pressure; Kirk Perry named interim CEO
- 2023-07J&J completes full separation of Kenvue via share exchange
- 2023-05Kenvue IPO raises $3.8B, largest US IPO since 2021
Revision history
20 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Kimberly-Clark to Acquire Kenvue (2025-11-02/03)
- Kimberly-Clark to Acquire Kenvue (2025-11-03)
- Kenvue - A new view of care (2026-07-14)
- Kenvue Q4/FY2025 Results (2026-02-17)
- Kenvue Reports First Quarter 2026 Results (2026-05-07)
- WSJ (2026-02-17)
- InsiderFinance (2026-02-18)
- AOL/Reuters (2026-07-15)
- ts2.tech (2026-07-19)
- MarketBeat (2026-07-20)
- FiercePharma (2025-07-15)